253. Inflammation in airway diseases: diagnosis and management

P2260
Additive role of exhaled NO and blood eosinophil count to predict wheezing in a random population sample
Andrei Malinovschi1, Joao Fonseca2, Tiago Jacinto3, Kjell Alving3, Christian Janzon4
1Dept. of Medical Sciences: Clinical Physiology, Uppsala University, Uppsala, Sweden; 2Dept. of Health Information and Decision Sciences, University of Porto, Portugal; 3Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden; 4Dept. of Medical Sciences: Respiratory Medicine and Allergology, Uppsala University, Uppsala, Sweden

The fraction of nitric oxide in exhaled air (FeNO) and blood eosinophil count (B-Eos), markers of local and systemic eosinophil activation, respectively, are increased in asthma. Little is known about the relation to reported wheezing in a random population sample or the additive value of these two methods.

FeNO (NIOX Mino) and B-Eos were measured in 12,408 subjects aged 6-79 years from the National Health and Nutrition Examination Survey 2007-08 and 2009-10. Current wheezing, hay fever and smoking habits were questionnaire-assessed. Subjects with wheezing had higher FeNO and B-Eos than subjects without wheezing (p<0.001). Slightly increased FeNO (25-50 ppb) and high FeNO (>50 ppb) related to a higher wheezing prevalence than normal FeNO (14% and 25% vs 12% for normal FeNO, p<0.001). Slightly increased B-Eos (300-500 Eos/mm³) and high B-Eos (>500 Eos/mm³) related to a higher wheezing prevalence than normal B-Eos (17% and 22% vs 11% for normal B-Eos, p<0.001). The risk of wheezing increased with increased B-Eos for subjects with high FeNO and, similarly, with increased FeNO for subjects with high B-Eos (Table).

<table>
<thead>
<tr>
<th>Risk of wheezing (odds ratio) with increased FeNO and B-Eos</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal B-Eos</td>
</tr>
<tr>
<td>Normal FeNO</td>
</tr>
<tr>
<td>Intermediate FeNO</td>
</tr>
<tr>
<td>High FeNO</td>
</tr>
</tbody>
</table>

Adjusted for gender, age, BMI, smoking and hay fever.

In conclusion, the prevalence of wheezing increased in this random population sample with increased FeNO and blood eosinophil count and the predictive values of these biomarkers for wheezing is additive. The clinical importance of these findings in asthma with regard to phenotyping and individualized treatment has to be determined.

P2261
The effect of long-term macrolides therapy for acute exacerbation of chronic obstructive pulmonary disease: A meta-analysis
Guoyan Yao1,2, Moqin Zhang1, Zhancheng Gao1, Yanliang Ma1
1Respiratory and Critical Care Medicine, Peking University People’s Hospital, Beijing, China; 2Respiratory Medicine, Beijing Fengtai Hospital, Beijing, China

Introduction: Chronic obstructive pulmonary disease (COPD) exacerbations are associated with frequent hospital admission reduction of lung function, and decreased quality of life. Macrolides have airway antiinflammatory actions and may reduce the frequency of COPD exacerbations.

Methods: We searched PubMed and Embase databases to identify randomized
controlled trials (RCTs) that assessed the effect of long-term macrolides therapy for COPD. The primary outcome assessed was frequency of acute exacerbations during follow-up. Both the fixed and random-effects models were used to obtain the hazard ratio of exacerbations associated with the use of macrolides versus controls or placebo depending on the heterogeneity of effects among studies.

**Results:** Combining six studies (N=1485), use of macrolides showed a decrease relative to no treatment of 0.73 (95% CI 0.59-0.92; P=0.03), compared to 0.71 (95% CI 0.51-0.95; P=0.03) in patients with asthma with bronchiectasis. The use of macrolides showed a significant effect on the number of patients experiencing acute exacerbation of COPD (point estimate 0.56; 95% CI 0.46-0.78; P=0.001) but also number of patients with at least one exacerbation (RR=0.5, 95% CI 0.27-0.92; P=0.02). Five studies reported adverse events, and adverse events were more frequent with macrolides (RR=1.35, 95% CI 1.09-1.67; P=0.001).

**Conclusions:** Long-term macrolide therapy in patients with COPD can decrease exacerbations, but the safety is not sure.

**P2262**

The CT emphysema index is a predictor for exertional desaturation in COPD patients without resting hypoxemia

Chanthawan Kim1, Yong Bum Park1, Joon Beom Seo2, Yeon-Mok Oh1, Sang-Do Lee1.1. Department of Pulmonary and Critical Care Medicine, Hallym University Kangdong Sacred Heart Hospital, Seoul, Korea; 2. Department of Radiology, and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Background: Although numerous studies have attempted to correlate various clinical tests with exertional desaturation in patients with COPD, no test has shown significance in predicting the value. The aim of this study was to identify clinical predictors of exertional desaturation focusing on the CT indices, and to determine whether an association exists between exertional desaturation and a particular COPD phenotype.

**Methods:** A total of 224 subjects were selected from the Korean Obstructive Lung Disease cohort. Exertional desaturation was defined as a post-exercise oxygen saturation (SpO2) of <90% or a ≥4% decrease. The cohort was divided into desaturator (n=47) and non-desaturator (n=177) groups.

**Results:** Significant differences were observed between the groups in terms of age, BODE index, forced expiratory volume in 1 second (FEV1), diffusing capacity, and desaturator (n=47) and non-desaturator (n=177) groups.

Conclusions: Significant differences were observed between the groups in terms of age, BODE index, forced expiratory volume in 1 second (FEV1), diffusing capacity, and desaturator (n=47) and non-desaturator (n=177) groups.

**P2263**

Managing asthma in the outpatient clinic: Is the diagnosis of asthma being made objectively according to guidelines?

Lise Stensø, Celeste Porborg, Aage Sverrild, Birgitte Nybo Jensen, Vibeke Backer. Respiratory Research Unit, Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark.

Background: BGINA guidelines recommend that a diagnosis of asthma is confirmed by an objective measurement of lung function or the presence of airflow hyperresponsiveness. However, currently no diagnostic flowchart exists on asthma and objective tests are used inconsistently.

**Aim:** To examine the use of diagnostic tests in newly referred patients with possible asthma in a specialized outpatient clinic.

**Methods:** The MAPOut I study is a retrospective observational study of all patients consecutively referred to a tertiary hospital specialist clinic over a 12-month period, on suspicion of asthma (n=221).

Data on lung function, peak flow, reversibility to beta2-agonist and airway hyperresponsiveness (AHR) was collected.

**Results:** Of 221 patients referred to the outpatient clinic with possible asthma, 128 (58%) were diagnosed with asthma. At least one objective test was performed in 103 (80.5) of the 128 subjects diagnosed with asthma (reversibility (57.8%), bronchial provocation (53.1%), PEF monitoring (50.9%). Among these 128 subjects, 80 had at least one positive test confirming presence of disease, corresponding to 63% of all subjects diagnosed with asthma.

**Conclusion:** Among patients diagnosed with asthma in a tertiary specialist clinic, the diagnosis of asthma was confirmed objectively in 63%. In a significant proportion of patients, treatment decisions were based solely on the presence of symptoms.

**P2264**

The effect of bronchectasis on asthma exacerbations

Ju-Hyoung Lee1, Byoung Hoong Lee2, Sanghoon Kim. Internal Medicine, Eulji Hospital, Seoul, Korea

Background: Bronchiectasis and asthma are different disease, however, some patients have both diseases. There are insufficient data for the effect of bronchectasis on asthma exacerbations.

**Methods:** We investigated 2270 patients having asthma in our hospital. Fifty patients had bronchiectasis and asthma. These patients were compared with fifty age and gender matched patients having asthma only. We evaluated frequency of asthma exacerbations (steroid use, emergency room (ER) visit and hospitalization) in each group.

**Results:** The prevalence of bronchiectasis among the asthma patients was 2.2%. Follow up duration of each group was 51.9±35.2 months for asthma with bronchiectasis and 53.8±29.8 months for pure asthmatics. The number of asthma exacerbations/year (1.08±1.68 vs 0.35±0.42; p=0.004), steroid use/year (0.94±1.54 vs 0.26±0.36, p=0.006), ER visit/year (0.46±0.84 vs 0.26±0.36, p=0.001) and hospitalization/year (0.7±1.44 vs 0.1±0.17, p=0.04) due to asthma exacerbation were higher in asthma with bronchiectasis than pure asthma.

**Conclusion:** The number of asthma exacerbation, steroid use, and ER visit due to asthma exacerbation was higher in asthma with bronchiectasis than pure asthma.

**P2265**

Adherence to asthma treatment: Can it be improved in general practice?

Maja Bornemann1, Vibeke Backer. Respiratory Research Unit, Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark.

Background: Good treatment adherence is pivotal in maintaining well-controlled asthma, along with the right diagnosis and the right treatment.

**Aim:** In a GP setting, we aimed to study changes in adherence to asthma treatment among asthmatic patients when using a systematic asthma consultation guide based on the Global Initiative for Asthma (GINA) guidelines.

**Methods:** The study comprised 2148 patients aged 18-79 years with doctor-diagnosed asthma from 130 clinics across Denmark. When managing the patients, the GPs were instructed to follow the consultation guide based on the principles of the GINA guidelines. This included evaluation of symptoms, treatment, adherence, lung function, and a scheduled follow-up appointment based on the level of asthma control. Adherence and use of medication were determined using a questionnaire as part of the consultation with a trained asthma nurse.

**Results:** At the date of analysis 706 patients had attended both baseline and follow-up visit. At baseline visit 542 (76.8%) patients were classified as having good adherence, and 94 (13.3%) as having low adherence. A significant positive predictive value. The aim of this study was to identify clinical predictors of exertional desaturation focusing on the CT indices, and to determine whether an association exists between exertional desaturation and a particular COPD phenotype.

**Methods:** A total of 224 subjects were selected from the Korean Obstructive Lung Disease cohort. Exertional desaturation was defined as a post-exercise oxygen saturation (SpO2) of <90% or a ≥4% decrease. The cohort was divided into desaturator (n=47) and non-desaturator (n=177) groups.

Conclusions: Significant differences were observed between the groups in terms of age, BODE index, forced expiratory volume in 1 second (FEV1), diffusing capacity, and desaturator (n=47) and non-desaturator (n=177) groups.

**P2266**

Risk factors associated with persistent airflow limitation in difficult asthma


Introduction: The clinical manifestations of difficult asthma are heterogeneous. Some patients with difficult asthma develop irreversible airway obstruction, which is associated with poor outcomes.

**Objective:** The aim of the study is to determine clinical characteristics associated with persistent airflow limitation in difficult asthma.

**Methods:** We retrospectively analyzed 48 patients with difficult asthma between 2005 and 2010. Twenty patients (8 female, 12 male) with persistent airflow limitation (post bronchodilator FEV1/FVC ratio < 70%) were compared to 28 patients (13 female, 15 male) with normal post bronchodilator FEV1/FVC ratio. Patients with chronic obstructive pulmonary disease and bronchiectasis were excluded.

**Results:** There was no significant difference between the two groups in age (51 vs 45 years, p=0.17), sex (p=0.66), age of asthma onset (55 vs 32 years, p=0.07), number of hospitalizations (p=0.39) and frequency of exacerbations (p=0.74). Rhinitis was more frequent in patients with chronic obstructive pulmonary disease and bronchiectasis were excluded.

**Conclusions:** In patients with difficult asthma, smoking, longer disease duration and absence of sensitization seem to be related to persistent airflow limitation in Tunisian patients with difficult asthma.
P2267 Can we achieve GINA guidelines described asthma control in a developing country?
Kaleem Ullah Toori1, Sumairah Nabi2. 1Department of Medicine, KRL Hospital, Islamabad, Pakistan; 2Department of Medicine, Pakistan Institute of Medical Sciences, Islamabad, Pakistan

Introduction: In Pakistan, 5% of adult population suffer from asthma. Poor disease control accounts for morbidity and recurrent hospitalization. Prospective studies assessing asthma control in Pakistan are lacking.

Aims & Objectives: To assess asthma control and factors predicting good asthma control.

Methods: Consecutive 50 asthmatic patients were studied in this prospective, interventional study from April to December, 2010. Diagnosis was confirmed by rise in FEV1 of ≥12% after bronchodilator. Patients were assessed during intervention period at weeks 0, 4 and 8 and finally after 6 months. Data was analysed using SPSS version 17.

Results: Mean age was 43 years with predominant females (66%). 50% were in lower social class and 58% had family history of asthma. Majority belonged to mild (42%) or moderate (48%) persistent varieties of asthma. At initial assessment 24% used inhalers correctly and 52% required treatment modification according to GINA guidelines. At completion of intervention period 70% had well controlled asthma, 60% used inhaler correctly and 66% were compliant with treatment. At completion of non-interventional period (after 6 months) only 40% had well controlled asthma, 44% used inhalers correctly and 50% were compliant with treatment. A linear regression analysis recognised correct inhaler technique and treatment compliance as significant predictors of good asthma control while age, gender, social class, educational level, severity and family history of asthma were not of any significance in this regard.

Conclusions: GINA guidelines stated asthma control is achievable in our setting provided repeated patient education, correct inhaler technique and compliance to medical therapy are ensured.

P2268 Long term inhalatory therapy in asthma – Achieving control of the disease
Lavinia Davidescu, Angelina Aurea, Ruxandra Ulmeanu. Pneumology, Pneumology Hospital Oradea, Oradea, Romania

Objective: Evaluation of long term inhalatory therapy in asthma and achieving control of the disease using asthma control test.

Methods: This was a prospective study recruiting ambulatory patients aged ≥12 years with asthma at the Pneumology Hospital Oradea between December 2011 and January 2012. We evaluate the effectiveness of long term inhalatory treatment of the disease with ACT as a means of detecting GINA defined uncontrolled, partially controlled and controlled asthma (uncontrolled and partially controlled asthma are together labeled as “not controlled” according to GINA). Patients with the following were included in the study: hospitalized for asthma and ambulatory patients with asthma. The questionnaire used was ACT Romanian and English version for adults from www.asthmacontroltest.com. Eligible patients answered and submitted the questionnaire to the investigator, patients then performed Spirometry tests followed by an interview with a pulmonologist who evaluated their asthma control and provided treatment modifications as required.

Results: Among 60 patients participating in the study of mean age 55 years. Females comprised of 55% of the participants and 45% maleparticipants. A mean ACT score was 15.05, in which GINA stage 1 and 3 are prominent 35%, but in general patients are unequally distributed among the four stages. Most of the patients were using preventive medication; the majority had uncontrolled asthma according to both GINA and ACT criteria and were stepped up on treatment after their visit.

P2269 Comparing COPD care in Malta, to other European hospitals: Results from the ERS COPD audit
Eleanor Gerada, Jospehine Bigeni, Cynthia Farrugia Jones. Department of Respiratory Medicine, Mater Dei Hospital, Msida, Malta

Background: Proper management of COPD can reduce exacerbations, which in turn reduces disease-related mortality.

Aim: To find out how management of COPD exacerbations in Malta contrasts with other countries.

Methods: A total of 422 European hospitals took part. Every COPD patient admitted with an exacerbation to our hospital over 8 weeks, was included (n=112). The ERS COPD audit proforma and web tool was used. Data was processed by the Data Analysis Team. The authors take full responsibility for any inferences made in this abstract.

Results: The median length of stay was 5 days, while the European Median (EM) was 8 days; there is no early supported discharge programme locally (31.8% of European hospitals run this). The 90-day readmission rate in Malta was 47.6% locally vs. 35.1% EM. In Malta there is no respiratory ward (81.7% EM), no specialist COPD Centre, Beaumont Hospital, Dublin, Ireland

Background: In Pakistan, 5% of adult population suffer from asthma. Poor disease control accounts for morbidity and recurrent hospitalization. Prospective studies assessing asthma control in Pakistan are lacking.

Aims & Objectives: To assess asthma control and factors predicting good asthma control.

Methods: Consecutive 50 asthmatic patients were studied in this prospective, interventional study from April to December, 2010. Diagnosis was confirmed by rise in FEV1 of ≥12% after bronchodilator. Patients were assessed during intervention period at weeks 0, 4 and 8 and finally after 6 months. Data was analysed using SPSS version 17.

Results: Mean age was 43 years with predominant females (66%). 50% were in lower social class and 58% had family history of asthma. Majority belonged to mild (42%) or moderate (48%) persistent varieties of asthma. At initial assessment 24% used inhalers correctly and 52% required treatment modification according to GINA guidelines. At completion of intervention period 70% had well controlled asthma, 60% used inhaler correctly and 66% were compliant with treatment. At completion of non-interventional period (after 6 months) only 40% had well controlled asthma, 44% used inhalers correctly and 50% were compliant with treatment. A linear regression analysis recognised correct inhaler technique and treatment compliance as significant predictors of good asthma control while age, gender, social class, educational level, severity and family history of asthma were not of any significance in this regard.

Conclusions: GINA guidelines stated asthma control is achievable in our setting provided repeated patient education, correct inhaler technique and compliance to medical therapy are ensured.

P2270 Clinical features of alpha one antitrypsin deficiency in COPD
Mohammed Badawy, Atif Farouk, Hamdy Mohammadn. Chest Department, South Valley University, Luxor, Egypt Chest Department, Assiut University, Assiut, Egypt Chest Department, Sohag University, Sohag, Egypt

Setting: About 1.3% of patients with diagnosed chronic obstructive pulmonary disease (COPD) are predicted to have alpha1-antitrypsin deficiency (A1ATD).

Aim: To clinically evaluate and increase recognition of A1ATD in patients with COPD.

Material and methods: Sixty COPD patients were diagnosed on the basis of clinical and pulmonary function tests. They fulfilled the inclusion criteria and divided into group (A) COPD below 40 years (30 cases) and group (B) COPD above 40 years (30 cases). All patients were subjected thorough history taking, radiological examination, blood gas analysis and quantitative measurements of serum-alpha-1-antitrypsin by radio-immunoassay.

Results: Mean age of group A&B were (44.17±2.75, 61.87±6.04) respectively with (p value <0.001). The mean serum level alpha 1 antitrypsin in group A&B were (188.03±23.00 with only one case deficient&177.5±49 with only four cases deficient) respectively without statistical significance. There is significant relationship between the age of the patient and A1ATD, where in deficient patients mean age 39.6±13.66, and in normal patients mean age 50.18±12.06 with (P value 0.02). There is also significant relationship between family history and A1ATD, where in deficient patients 50%of cases (4 cases) had positive family history, in contrast to 11.6% of cases(13 case) of normal patients (p value 0.003).

Conclusion: Alpha1 antitrypsin deficiency is very low in Malta compared to other countries which is consistent with the current literature. There is significant difference between deficient and normal group as regards gender distribution, smoking history, symptomatic presentations, physical signs, radiological picture, pulmonary function tests and blood gas parameters.

P2271 Chronic kidney disease (CKD) – A forgotten co-morbidity in COPD
Nawaid Ahammad, Humam Masued, Raana Haque. Respiratory Medicine, New Cross Hospital, Bexleyheath, United Kingdom Respiratory Medicine, New Cross Hospital, Bexleyheath, United Kingdom

Background: CKD is a less recognized co-morbidity in COPD and its impact on exacerbations and mortality has been under reported.

Objectives: To look at the prevalence of CKD at admission to hospital with exacerbation of COPD. Secondly, to compare the length of stay (LOS) in hospital and all cause mortality between the CKD and non-CKD cohort.

Methods: We included all patients admitted to hospital with a COPD exacerbation from 1st January 2010 to 31st December 2010. COPD was defined as eGFR<60ml/min/m2 for at least 3 months. Data was analysed by independent sample t-test, chi-square and Mann Whitney U test using online tool Vassar stats and significance reported at p<0.05.

Results: 161 patients (56% females) were admitted each with FEV1/FVC ratio<0.7 and median FEV1 36% predicted. Spirometry and BMI data were analysed on 113 patients (CKD n= 90, non-CKD n=23) as records for 48 patients could not be obtained. The prevalence of CKD was 18.6% (n=30). CKD group, was older (mean age 75.8 yrs vs 69.2 yrs; p=0.001), included more males (45% vs 43%), had higher Body Mass Index (30 vs 23.8 kg/m2; p= 0.002), had better FEV1 (46 vs 35.5% predicted; p= 0.02) and longer LOS (8 vs 6 days; p=0.042). There was no significant difference in mortality between the two groups (n= 7 vs n=30; p=0.84).

Conclusion: CKD is prevalent in COPD and has a significant effect on the LOS during exacerbations; however it does not contribute to increased one year mortality. Hence, more work is required in this field

References:
[1] ICD code J44.1

P2272 Characteristics of ze alpha-1 antitrypsin deficiency patients on the Irish national registry
Geraldine O’Brien, Catherine O’Connor, Tomas Carroll, N.G. McElvany. Respiratory Research, Department of Medicine, RCSI Education and Research Centre, Beaumont Hospital, Dublin, Ireland

Rationale: Alpha-1 antitrypsin (AAT) is produced by hepatocytes, and is the
most important antiprotease in the lung. AAT deficiency (AATD) is a hereditary disorder resulting from mutations in the AAT gene. Individuals with this deficiency classically present with lung disease in adulthood. WHO guidelines advocate a targeted strategy in screening COPD, non-respiratory asthma, cryptogenic liver disease patients and relatives of known AATD patients.

Methods: The most common AAT phenotype associated with lung disease is ZZ. A chart review of AATD patients on the National Alpha-1 Registry was performed on ZZ patients (n=100). Our registry collects data on pulmonary function tests, GOLD guidelines, initial reason for screening, complications, and smoking history. Results: We found that ZZ individuals identified as a result of family screening, who were symptomatic or asymptomatic, had significantly increased FEV1 (85.3±6.5%, 40.8±2.8%) compared to ZZ patients identified by targeted symptomatic screening (54.3±8.9%, 46.8±1.8 years, p<0.0008). ZZ patients with a history of smoking had significantly decreased lung function (FEV1, 54.8±3.9%, 43.7±1.6 years) compared to never-smoking ZZ individuals (FEV1, 88.2±4.8%, 43.3±4.6 years, p<0.001). No significant difference was found with COPD patients and ZZ individuals with normal lung function.

Conclusions: Our results highlight the role of cigarette smoke in the pathogenesis of lung disease in AATD and the need for increased awareness and early detection of symptomatic AATD. Identification of patients from a targeted detection programme should include aggressive family screening and allow the initiation of preventative measures before significant lung disease has occurred.

P2275 Lung function decline in adult asthmatics. A 10-year follow-up
Giuseppe Cumin, Salvatore Buccheri, Fabio Cibella, Mario Melisi, Atef Farouk1, Atef Farouk2, Hamdy Mohammdien 3, Salvatore Bucchieri, Fabio Cibella, Mario Melis, 1, Atef Farouk2, Hamdy Mohammdien 3. Respiratory Therapy, Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia; 2Health Sciences, University of Southampton, United Kingdom

Computer technology was used to record and analyse lung sounds in two groups of healthy young subjects (smokers and non-smokers).

Introduction: Tobacco smoking is known to have adverse effects on human health. It is believed that smoking in early life has a substantial role in the development of chronic lung disease, but it is not yet known when the first measurable effects of smoking can be detected. Computer aided lung sound analysis (CALSA) permits the quantification of lung sounds, which may change in response to smoking induced pathological processes. Crackles are one type of added lung sound which can be quantified using CALSA.

Method: Sixty male subjects (30 smokers and 30 non-smokers) aged 26-64 years, were recruited from a student population. Lung sound recordings were made using a digital stethoscope, following published guidelines. Sounds were recorded on a computer with Matlab software. Using signal processing techniques, one characteristic of the crackles was measured (namely the two cycle deflection (2CD)) at each anatomical recording site. Statistical analysis was used to quantify differences in crackles between smokers and non-smokers.

Results: Sixty sets of data have been analysed. The 2CD per site data revealed statistically significant differences at both anterior sites (anterior left: F(2,57)=3.79, P=0.03; anterior right: F(2,57)=4.29, P<0.05) and at the midline level (middle left: F(2,57)=4.2, P=0.02; middle right: F(2,57)=4.2, P=0.02). The best FEV1 measures at 1st, 5th and 10th year were evaluated using a digital stethoscope, following published guidelines. Sounds were recorded on a computer with Matlab software. Using signal processing techniques, one characteristic of the crackles was measured (namely the two cycle deflection (2CD)) at each anatomical recording site. Statistical analysis was used to quantify differences in crackles between smokers and non-smokers.

Conclusion: The hypothesis that lung crackles decrease with smoking has been supported.

P2277 Clinical features of alpha one antitrypsin deficiency in non cystic fibrosis bronchiectasis
Mohamed Badawy 1, Atef Farouk 2, Hamdy Mohammdien 3. 1Chest Department, South Valley University, Qena Faculty of Medicine, Luxor; 2Chest Department, Assiut University, Assiut; 3Chest Department, Sohag University, Sohag, Egypt

Setting: It’s important to identify manifestation of alpha-I antitrypsin deficiency (A1ATD) in bronchiectasis to improve patients care and outcome.

Objective: To clinically evaluate A1ATD in patients with non cystic fibrosis bronchiectasis.

Material and methods: Patients with non cystic fibrosis bronchiectasis were diagnosed clinically and confirmed radiologically. They fulfilled the inclusion criteria and divided into group (A) bronchiectasis with hyperinflation (30 cases) and group (B) bronchiectasis without hyperinflation (30 cases). All patients were subjected to history taking, pulmonary function tests, and quantitative measurements of serum α1-antitrypsin by radioimmunoassay.

Results: Mean age of both groups was (50±6.8) and (36.8±11.3) respectively (P=0.001). There were significant difference in gender distribution (p=0.006), and smoking history (p=0.001). Neumophtysis present in 12 cases (40%), and 20 cases (66.67%) in both groups respectively (p=0.04). Dyspnea presented in 27 cases (90%) and 19 cases (63%) for group A&B with (P=0.02). There were no significant difference in sigmoidism, hepatopulmonary symptoms, clubbing and family history. There were significant differences in the lung function tests, radiological findings and spirometric tests (P value 0.01, 0.004, 0.001, 0.001, 0.001, 0.001, 0.001, 0.001, 0.001, 0.001).
0.001, 0.001) respectively. Three cases (5%) of A1ATD were diagnosed among all patients’ one case (1.5%) in group (A) of MZ allele and two brother cases (3.5%) in group (B) of SZ allele without statistical significance.

**Conclusion:** A1ATD is seldom found in patients with bronchiectasis even with concomitant hyperinflation. Inheritance could influence an individual risk of A1ATD for developing bronchiectasis.

**P2278**

Clinitmetric properties of outcome measures in bronchiectasis

Stephen Rowan1, Joseph Stuart Elborn1, Madeleine Ennis1, Judy Bradley2.

1Centre for Infection and Immunity, Queen’s University Belfast, United Kingdom; 2School of Health Sciences, University of Ulster, Belfast, United Kingdom

**Introduction:** In bronchiectasis (BE) there is demand for researchers and regulatory bodies to use robust outcome measures (OM) in clinical trials which have evidence of validity, reliability and responsiveness.

**Aim:** To explore the evidence for clinitmetric properties of commonly used outcome measures in BE.

**Methods:** A systematic search of key databases (2000-2010) to identify studies in adults with BE which included the following OM: HRCT, FEV1, Quality of life (QoL), exacerbations (PEX), sputum volume/colour, and sputum inflammatory markers (IL-8 and elastase). Data relating to clinitmetric properties was extracted.

**Results:** 68 papers met the inclusion criteria. There was good evidence for all components of validity for HRCT, FEV1, QoL, and with exception of predictive validity for sputum volume/colour and sputum inflammatory markers. There was minimal evidence for validity for PEX. The majority of RCTs in BE included FEV1 (n=9/11) as a key OM however none were able to demonstrate a treatment effect with FEV1. Other research designs (e.g. crossover/cohort studies) were also unable to demonstrate a treatment effect with FEV1. A small number of RCTs (n=5) included the other OM and some of these studies were able to demonstrate a significant treatment effect (QoL n=2/4, PEX n= 2/4, sputum volume/colour n=1/5 and sputum inflammatory marker n=1/5). Other research designs were also able to demonstrate a treatment effect with these outcomes.

There are a small number of studies demonstrating test-retest reliability of these OM.

**Conclusions:** FEV1 is considered to be the primary outcome in clinical trials however current evidence in BE suggests that FEV1 may not be responsive and other outcome measures should be considered.

**P2279**

PCD – As serious as CF in every day lung clinic?

Annika Hollsing. Dept. Women’s and Child Health, Uppsala University, Uppsala CF Center, Uppsala, Sweden

**Background:** Cystic fibrosis, CF, and Primary cilia dyskinesia, PCD, have very different genetic background, but present very similar in clinic with vicious mucus, bacteria, bronchiectasis and negatively affected lung function. Our regimen involves mucolytica, inhalations, airway clearance and anti-bacterial treatment regardless of diagnosis, but in all cases individualized.

**Aim of study:** To see whether PCD patients as a group were as affected as CF patients.

**Patients:** All patients, CF and PCD, seen regularly at our clinic were compared as a whole group and also in an age and gender matched subgroup of 21 pairs.

**Results:** When comparing lung function in the two groups, FEV1 (in percentage of expected for age and length) showed, to our surprise, to be worse for the PCD group, both in the main group and in the subgroup.

The bronchiectases are evaluated separately and will be presented at the Conference.

There were more, but not exclusively, pseudomonas infections in the CF group – 38 vs 14%. There was no B cepacia or S maltophilia in the PCD group.

The BMI was as expected a little lower in the CF group.

**Conclusions:** The more affected lung function amongst the PCD patients could be due to later diagnosis and less importance given to lung treatment. The focus on early diagnosis, effective inhalation and treatment regimen in the CF group have resulted in better results despite the very complex and severe disease.